维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="SOLIT D"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Development and application of Hsp90 inhibitors显示文摘	Solit D B Chiosis G	2008	Drug Discov Today2008，13，12：	1
2	New Efficient Synthesis of ResorcJnylic Macrolides via Ynolides: Establishment of Cycloproparadicicol as Synthetically Feasible Preclinical Anticancer Agent Based on Hsp90 as the Target 显示文摘	YANG Z GENG X SOLIT D	2004	J Am Chem Soc2004，126，：	1
3	KRAS and BRAF: drug targets and pre- dictive biomarkers显示文摘	Vakiani E Solit D B	2011	J Pathol2011，223，2：	1
4	Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol显示文摘	Solit D B Basso A D Olshen A B	2003	Cancer Res2003，63，9：	1
5	Modulation of Hsp90 function by ansamycins sensitizes breast cance cells to chemotherapy-induced apoptosis in an RB-and schedule-dependent manner 显示文摘	Munster PN Basso A Solit D	2001	Clin Cancer Res2001，7，：	1
6	BRAF mutation predicts sensitivity to MEK inhibition 显示文摘	SOLIT D B GARRAWAY L A PRATILAS C A	2005	Nature2005，439，7074：	1
7	Inhi- bition of heat shock protein 90 function down-regu- lates Akt kinase and sensitizes rumors to taxol 显示文摘	SOLIT D B BASSO A D OLSHEN A B	2003	Cancer Res2003，63，9：	1
8	Akt forms an intracellular complex with heat shock protein 90(Hsp90)and Cdc37 and is destabilized by inhibitors of Hsp90 function显示文摘	Basso A D Solit D B Chiosis G	2002	J Biol Chem2002，277，39：	1
9	A phase I trial of intermittcnt high-dose gefitinib and fixed-dose docetaxel in patients with ad vanced solid tumors 显示文摘	Fury M G Solit D B Su Y B	2007	Cancer Chemother Pharmacol2007，59，4：	1
10	Phase 1I trial of 17- allylamino-17-demethoxygeldanamycin in patients with me-tastatic melanoma 显示文摘	Solit DB Osman I Polsky D et ol	2008	Clin Cancer Res2008，14，24：	1
11	Inhi- bition of heat shock protein 90 function down-regu- lates Akt kinase and sensitizes tumors to taxol 显示文摘	SOLIT D B BASSO A D OLSHEN A B	2003	Cancer Res2003，63，9：	1
12	BRAF mutation predicts sensitivity to MEK inhibition显示文摘	SOLIT D B GARRAWAY L A PRATILAS C A	2005	Nature2005，439，：	1
13	Pulsatile Administration of the Epi- dermal Growth Factor Receptor ]nhibitor Gditinib Is Significantly More Effective than Continuous Dosing for Sentitizing Tumors to Paclitaxel显示文摘	Solit D B She Y Lobo J	2005	Clin Cancer Res2005，11，5：	1
14	Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function显示文摘	Basso A D Solit D B Chiosis G	2002	J Biol Chem2002，277，39：	1
15	BRAF mutation predicts sensitivity to MEK inhibition 显示文摘	SOLIT D B GARRAWAY L A PRATILAS C A	2005	Nature2005，439，7074：	1
16	Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol显示文摘	Solit D B Basso A D Olshen A B	2003	Cancer Res2003，63，9：	1
17	BRAF mutation predicts sensitivity to MEK inhibition显示文摘	Solit D B Garraway L A Pratilas C A	2005	Nature2005，439，7074：	1
18	Imaging the pharmaeodynamics of HER2 degradation in response to Hsp90 inhibitors显示文摘	SMITH-JONES P M SOLIT D B AKHURST T	2004	Nature Biotechnology2004，22，6：	1
19	Drug discovery: How melanomas bypass new therapy 显示文摘	Solit D Sawyers CL	2010	Nature2010，468，7326：	1
20	Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemo therapy induced apoptosis in an RB- and schedule-dependent manner显示文摘	MOnster PN Basso A Solit D	2001	Clin Cancer Res2001，7，22：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示